Form 4: Entrada director sells 200k TRDA shares

Entrada Therapeutics director and 10% owner Kush M. Parmar reported selling 200,000 shares at a weighted average price of $8.80, retaining 4,056,379 shares indirectly via 5AM funds.

Summary

• Kush M. Parmar, M.D., Ph.D., a director and 10% owner of Entrada Therapeutics (TRDA), sold 200,000 common shares on 2025-11-14 (transaction code S).
• The reported price is a weighted average of $8.80, with individual trades executed between $8.80 and $9.023.
• Post-transaction indirect holdings total 4,056,379 shares: 2,963,066 shares via 5AM Ventures V, L.P. and 1,093,313 shares via 5AM Opportunities I, L.P.
• The sale and holdings are reported as indirect, through 5AM-affiliated funds; Dr. Parmar may be deemed to share voting and investment power but disclaims beneficial ownership except to the extent of his pecuniary interest.
• The reporting person undertakes to provide the full breakdown of shares sold at each price within the stated range upon request.
• Implied pre-transaction holdings at 5AM Ventures V, L.P. were 3,163,066 shares (2,963,066 after plus 200,000 sold).

Sentiment

Score: 4

Explanation: Moderately negative due to insider selling by a director and 10% owner, partially offset by substantial remaining indirect holdings and transparent disclosure.

Positives

• Significant continuing indirect ownership of 4,056,379 shares suggests ongoing exposure to the company.
• Clear disclosure of a price range ($8.80–$9.023) and offer to provide detailed trade data enhances transparency.
• No derivative securities activity disclosed; transaction limited to common stock.

Negatives

• Insider sale by a director and 10% owner (200,000 shares) can be perceived negatively by the market.
• Sale price around $8.80 indicates monetization near the lower end of the disclosed range.
• Reduction appears concentrated in 5AM Ventures V, L.P., implying portfolio trimming at that fund (implied decrease of 200,000 shares).

Future Outlook

No forward-looking statements provided.

Management Comments

• The reported sale price is a weighted average; individual trades ranged from $8.80 to $9.023.
• Full information on the number of shares sold at each price within the range will be provided upon request.
• Shares are held indirectly via 5AM Ventures V, L.P. and 5AM Opportunities I, L.P.; the reporting person may be deemed to share voting and investment power but disclaims beneficial ownership except for his pecuniary interest.

Industry Context

Insider sales by venture-affiliated directors are common in biotech and often reflect fund-level portfolio management rather than changes in company fundamentals; such transactions alone typically do not indicate an operational shift.

Comparison to Industry Standards

• The sale size (~200k shares) and implied reduction of roughly 5% of total indirect holdings align with routine insider liquidity events often seen among venture-backed biotechs.
• Similar patterns of periodic insider sales are observed at peers in the biotech sector following major milestones or lockup expirations; transaction structure and disclosure are consistent with industry norms.
• No deviation from standard Form 4 disclosure practices (price range, weighted average, indirect ownership via funds) relative to comparable companies.

Stakeholder Impact

• Shareholders may perceive the sale by a 10% owner as a negative sentiment signal.
• Market liquidity may increase modestly due to additional shares sold into the market.
• No change to corporate control indicated; substantial indirect holdings remain with 5AM-affiliated funds.

Next Steps

• Provide detailed breakdown of shares sold at each price within the disclosed range upon request (as noted by the reporting person).

Key Dates

Keywords

Entrada Therapeutics, TRDA, Form 4, insider transaction, insider selling, Kush Parmar, 5AM Ventures, beneficial ownership, biotech, venture-backed, SEC filing